Lumoxiti
Drug
Innate Pharma, Inc
Total Payments
$435,419
Transactions
151
Doctors
135
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2021 | $172,701 | 28 | 14 |
| 2020 | $262,718 | 123 | 121 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $363,069 | 22 | 83.4% |
| Honoraria | $39,750 | 20 | 9.1% |
| Consulting Fee | $29,136 | 9 | 6.7% |
| Food and Beverage | $3,464 | 100 | 0.8% |
Payments by Type
Research
$363,069
22 transactions
General
$72,350
129 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Phase I Study of Moxetumomab Pasudotox-tdfk (Lumoxiti) and Rituximab (Rituxan) for Relapsed Hairy Cell Leukemia | Innate Pharma, Inc | $212,080 | 0 |
| A phase-I study of the anti-C5aR, IPH5401, in combination with the anti-PDL-1, durvalumab, in patients with selected advanced solid tumors | Innate Pharma, Inc | $150,989 | 6 |
Top Doctors Receiving Payments for Lumoxiti
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Bethesda, MD | $212,080 | 2 |
| , M.D. PH.D | Medical Oncology | New York, NY | $41,453 | 6 |
| Anthony Tolcher | Medical Oncology | San Antonio, TX | $38,453 | 6 |
| , M.D | Medical Oncology | Dallas, TX | $38,118 | 1 |
| , MD | Hematology & Oncology | Louisville, KY | $14,965 | 2 |
| , MD | Internal Medicine | Minneapolis, MN | $10,500 | 3 |
| , MD | Medical Oncology | New Haven, CT | $7,920 | 1 |
| , M.D | Medical Oncology | Nashville, TN | $7,500 | 2 |
| , MD | Dermatopathology | Charlottesville, VA | $7,424 | 1 |
| , M.D | Hematology | Columbus, OH | $4,200 | 1 |
| , M.D | Medical Oncology | Chicago, IL | $3,960 | 1 |
| , M.D | Hematology & Oncology | Philadelphia, PA | $3,900 | 1 |
| , M.D | Hematology & Oncology | Houston, TX | $3,500 | 1 |
| , D.O | Hematology & Oncology | Salt Lake City, UT | $3,300 | 1 |
| , MD | Hematology | Columbus, OH | $3,300 | 1 |
| , MD | Hematology & Oncology | Omaha, NE | $2,400 | 1 |
| , MD | Hematology & Oncology | Los Angeles, CA | $2,400 | 1 |
| , MD,MPH | Hematology & Oncology | Seattle, WA | $2,400 | 1 |
| , MD | Medical Oncology | Aurora, CO | $2,400 | 1 |
| , M.D | Internal Medicine | Duarte, CA | $2,400 | 1 |
| , MD | Internal Medicine | Detroit, MI | $2,400 | 1 |
| , MD | Internal Medicine | Portland, OR | $2,400 | 1 |
| , M.D | Hematology | Chicago, IL | $2,400 | 1 |
| , MD | Hematology | Albuquerque, NM | $1,813 | 1 |
| , MD | Internal Medicine | Tampa, FL | $1,800 | 1 |
Ad
Manufacturing Companies
- Innate Pharma, Inc $435,419
Product Information
- Type Drug
- Total Payments $435,419
- Total Doctors 135
- Transactions 151
About Lumoxiti
Lumoxiti is a drug associated with $435,419 in payments to 135 healthcare providers, recorded across 151 transactions in the CMS Open Payments database. The primary manufacturer is Innate Pharma, Inc.
Payment data is available from 2020 to 2021. In 2021, $172,701 was paid across 28 transactions to 14 doctors.
The most common payment nature for Lumoxiti is "Unspecified" ($363,069, 83.4% of total).
Lumoxiti is associated with 2 research studies, including "A Phase I Study of Moxetumomab Pasudotox-tdfk (Lumoxiti) and Rituximab (Rituxan) for Relapsed Hairy Cell Leukemia" ($212,080).